Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DART 2.0: ctHPV-DNA Informed De-Escalated Adjuvant and Definitive Radiation Therapy
NCT05541016Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Mar 2023
- Primary completion
- Sep 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial in oropharyngeal squamous cell carcinoma (OPSCC) (4 arms), sponsored by Mayo Clinic. Primary endpoint: Progression-Free Survival at 5 years. Started Mar 2023; status: recruiting.
02
Conditions
oropharyngeal squamous cell carcinoma (OPSCC)
Beyond the preview
Go deeper on NCT05541016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05541016.